Creative Medical Technology Holdings (CELZ) Net Income towards Common Stockholders (2010 - 2026)

Creative Medical Technology Holdings (CELZ) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$1.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 14.31% year-over-year to -$1.4 million; the TTM figure through Mar 2026 stood at -$6.1 million (up 15.39% YoY), while the FY2025 annual figure was -$6.3 million, up 4.21% from the prior year.
• Net Income towards Common Stockholders improved to -$1.4 million in Q1 2026 per CELZ's latest filing, from -$2.2 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$982339.0 in Q3 2022 and bottomed at -$6.2 million in Q4 2022.
• Historically, Net Income towards Common Stockholders has averaged -$1.8 million across 5 years, with a median of -$1.4 million in 2026.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 104.15% — and 2023, when it jumped 72.99%.
• Creative Medical Technology Holdings' Net Income towards Common Stockholders stood at -$6.2 million in 2022, then surged by 72.99% to -$1.7 million in 2023, then tumbled by 77.34% to -$3.0 million in 2024, then climbed by 25.09% to -$2.2 million in 2025, then surged by 37.05% to -$1.4 million in 2026.
• Business Quant data shows CELZ's Net Income towards Common Stockholders at -$1.4 million in Q1 2026, -$2.2 million in Q4 2025, and -$1.2 million in Q3 2025.